Clinical Ink, a global life science technology company and a portfolio company of GI Partners, has added Jonathan Goldman as chief executive officer.
Goldman succeeds Ed Seguine who has led Clinical Ink for nearly 14 years. He was most recently CEO of Abzena, where he remains a board member and was previously the CEO of Aptuit. He has also held senior executive positions at Icon Plc and Point Biomedical in addition to holding appointments as associate clinical professor of medicine in the division of cardiology at the University of California San Francisco, and as an attending cardiologist at the San Francisco Veterans Administration Medical Center.
“I’m excited to partner with patients and customers to drive biomarker adoption, simplify clinical trials, and provide novel insights into disease progression,” comments Goldman. “I studied medicine to offer solutions to patients. I am confident Clinical ink’s technology and operational prowess will be able to transform the therapeutic landscape by delivering a new era of diagnosis and treatment.”